Received Mar 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
received the second dose 2 months after the first dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a patient who received HAB (Twinrix) for prophylaxis. Concomitant products included HEPATITIS A VACCINE INACT;HEPATITIS B VACCINE RHBSAG (YEAST) (TWINRIX). On an unknown date, the patient did not receive the 2nd dose of Twinrix. On an unknown date, an unknown time after receiving Twinrix and an unknown time after receiving TWINRIX, the patient experienced drug dose administration interval too long (Verbatim: received the second dose 2 months after the first dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-MAR-2025 The pharmacist called to enquire on behalf of a patient what would happen if patient receive the 3rd dose of Twinrix in less than 6 months, was there any problem. Further the pharmacist asked, If they get the second dose 2 months from the 1st one, what could happen and at the beginning of the call the pharmacist said that it was a hypothetical situation. However, later in the call the pharmacist mentioned that a patient had already received the second dose 2 months after the first dose. The patient received 2nd dose of Twinrix, which led to lengthening of vaccination schedule.
TWINRIX